Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

5-Day radiation blast shows promise for containing spread of solid tumors

NCT ID NCT01761929

Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a 5-day course of high-dose radiation therapy (SBRT) for people with solid tumors that have spread to up to 5 spots in the body. The goal was to see if giving a stronger dose to the tumor while protecting normal tissue could control the disease and limit side effects. 138 participants were followed for one year to track how well the treated spots responded and any side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

138 people

The number who actually took part.

Started

Mar 2013

Finished

Feb 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Any solid tumors are eligible. Lymphoma, myeloma and germ cell tumors are excluded. * Histological confirmation of neoplastic disease either from original primary or metastatic sites is required. * Radiological diagnosis of oligometastastic metastatic disease is accepted if considered clinically acceptable. Histological confirmation is not mandatory. * Oligometastatic disease, maximum of 5 lesions. * At least one lesion is suitable for stereotactic body radiotherapy * All known sites of disease have plans for local ablative management (see section management plan for definitions) within 3 months * ECOG ≤ 2 * At least 18 yrs old Exclusion Criteria: * Previous radiotherapy to the intended treatment site * Patient cannot tolerate physical set up required for SBRT * Active bowel obstruction, if treating abdominal/pelvic site * Chemotherapy within 2 weeks of intended radiation therapy * Treatment plan respecting normal tissue tolerances using dose fractionation specified within the protocol cannot be achieved * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Solid tumors with oligometastatic spread are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metastatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Solid tumors with oligometastatic spread

Contacts and locations

Locations

  • University Health Network, Princess Margaret Cancer Center

    Toronto, Ontario, M5G 2M9, Canada